Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis

Cancer

Volumn 86, Issue 4, 1999, Pages 589-595

  Tarao, Kazuo ^a   Rino, Yasushi ^b   Ohkawa, Shinichi ^a   Shimizu, Akio ^a   Tamai, Setsuo ^a   Miyakawa, Kaoru ^a   Aoki, Hiroharu ^a   Imada, Toshio ^b   Shindo, Kunihiko ^b   Okamoto, Naoyuki ^a   Totsuka, Shinichi ^c  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

Hepatitis C virus associated cirrhosis; Hepatocellular carcinoma; Promotion; Serum alanine aminotransferase; Sho saiko to; Stronger neo minophager C

Indexed keywords

ALANINE AMINOTRANSFERASE; GLYCYRRHIZIC ACID; XIAO CHAI HU TANG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS;

AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 0033566684     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990815)86:4<589::AID-CNCR7>3.0.CO;2-K     Document Type: Article

References (29)

1. Slaga TJ, Scribner JD. Inhibition of tumor initiation and promotion by anti-inflammatory agents. J Natl Cancer Inst 1973;51:1723-5.
2. Cameron R, Lee G, Farber E. Chemical mitogens as effective alternatives to partial hepatectomy in the new model for the sequential analysis of hepatocarcinogenesis. Proc Am Assoc Cancer Res 1978;19:56.
3. Marks F, Bertsch S, Grimm W, Schweizer J. Hyperplastic transformation and tumor promotion in mouse epidermis: possible consequences of disturbances of endogenous mechanism controlling proliferation and differentiation. In: Slaga TJ, Sivak A, Boutwell RK, editors. Carcinogenesis. vol 2. New York, Raven Press, 1978:97-116.
4. Argyris TS. Tumor promotion by damage-induced epidermal hyperplasia in the skin of mice. Proc Am Assoc Cancer Res 1979;20:4.
5. Gratzner HG. Monoclonal antibody to 5-bromo-and 5-iodo-deoxyuridine: a new reagent for detection of DNA replication. Science 1982;218:474-6.
6. Tarao K, Shimizu A, Ohkawa S, Harada M, Ito Y, Tamai S, et al. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology 1992;103:595-600.
7. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, et al. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994; 73:1149-54.
8. Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y, Harada M, et al. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepato-cellular carcinoma. Jpn J Cancer Res 1994;85:1040-4.
9. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-75.
10. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine amino-transferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-94.
11. Tarao K, Shimizu A, Ohkawa S, Tamai S. Prediction of the development of hepatocellular carcinoma from HCV associated liver cirrhosis. J Jpn Soc Int Med 1995;84:1985-91.
12. Child CG III, Turcotte JG. Surgery and portal hypertension. In: Dunphy JE, editor. The liver and portal hypertension. Philadelphia: W.B. Saunders, 1964:50.
13. Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:10-24.
14. Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, et al. The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 1994;54:448-54.
15. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis-double blind trial. Asian Med J 1983;26:423-38.
16. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N. A multicenter randomized control clinical trial of Sho-saiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-9.
17. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993;19:459-64.
18. Tarao K, Tamai S, Ohkawa S, Miyakawa K, Aoki H, Takashimizu S, et al. The effects of combined drug therapy on the serum alanine aminotransferase levels in HCV-associated liver cirrhosis [in Japanese]. Rinsho-to Kenkyu 1998;75:1858-67.
19. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al. Prospective study of chemoprevention of hepato-cellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76: 743-9.
20. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
21. Lavanchy D. Hepatitis C: 170 million infected worldwide and still no vaccine [press release no. 36]. World Health Organization, May 1, 1998.
22. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, Chen TJ, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986;90:263-7.
23. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
24. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12: 680-7.
25. Ikeda K, Saito S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
26. Kaneko S, Unoura M, Takeuchi M, Terasaki S, Ogino H, Matsushita E, et al. The role of hepatitis C virus in hepato-cellular carcinoma in Japan. Intervirology 1994;37:108-13.
27. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
28. Jouet P, Roudot-Thoraval F, Dhumeaux D, Métreau J-M, Ie Groupe Francais pour l'Etude du Traitement es Hépatites Chroniques NANB/C. Comparative efficacy of Interferon alpha in cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-90.
29. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.